Pseudomonas Aeruginosa Infections Among COVID-19 Patients in Intensive Care Units at CHRU of Nancy (Pyo-COVID-3)

NCT06141837 | Completed

• 1 other identifier: 2023PI186
• Study Type: observational
• Target: 51
• Locations: 0 countries
• Sites: N/A

Brief Summary

P. aeruginosa is an opportunistic bacterium known to be responsible for numerous healthcare-associated infections, particularly in intensive care units (ICU). The frequency of these infections seems to have increased during the first waves of the COVID-19 pandemic. Identifying cases of co-infection and secondary infections with P. aeruginosa in patients with COVID-19 would provide a better understanding of the epidemiological evolution and characteristics of infected patients. Treatment of P. aeruginosa infections requires the use of antibiotics. Antibiotic resistance is a growing problem, with an increase in resistance among P. aeruginosa strains. The misuse of antibiotics to treat patients can accentuate the phenomenon of antibiotic resistance, and failure to take account of resistance revealed by antibiograms can compromise patient recovery. Analysis of bacteriological results and patient medical records would enable a posteriori evaluation of the proper use of antibiotics (choice and adaptation of molecules, doses and duration of prescriptions), and identify any areas for improvement. The main objective is to describe the evolution of P. aeruginosa infections in ICU patients with COVID-19 during the first 3 waves of COVID-19 (01/03/2020 to 31/05/2021). Secondary objectives are to describe the typology of P. aeruginosa strains identified among included patients (sampling sites and resistance profiles), to assess antibiotic prescriptions for these patients and to describe the relapse rate of included patients with a first P. aeruginosa infection.

Conditions

Pseudomonas Aeruginosa; COVID-19

Keywords

ICU infections; antimicrobial resistance

Outcome Measures

Primary Outcomes (1)

• P. aeruginosa occurence

  The occurrence of Pseudomonas aeruginosa infection during the ICU stay of a COVID-19 patient.

  From 01 March 2020 to 31 May 2021.

Secondary Outcomes (4)

• P. aeruginosa sample

  From 01 March 2020 to 31 May 2021.

• P. aeruginosa resistance

  From 01 March 2020 to 31 May 2021.

• P. aeruginosa antibiotic treatment

  From 01 March 2020 to 31 May 2021.

• P. aeruginosa recurrence

  From 01 March 2020 to 31 May 2021.

Study Arms (1)

Included

Patient hospitalized between 01/03/20 and 31/05/21 in an intensive care unit of the Nancy University Hospital for at less 48 h for COVID-19 acute respiratory distress syndrome and presenting a positive sample for P. aeruginosa during his stay in the intensive care unit.

Other: Observation

Interventions

Observation OTHER

No intervention: observational study

Included

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All patient hospitalized between 01/03/20 and 31/05/21 in an intensive care unit of the Nancy University Hospital for at less 48 h for COVID-19 acute respiratory distress syndrome and developed an hospital-acquired infection caused by P. aeruginosa during their stay in the intensive care unit.

You may qualify if:

• Adult patients hospitalized for at least 48 h in an intensive care unit (ICU) at CHRU-Nancy for acute respiratory distress syndrome due to COVID-19.
• Patients hospitalized from 1st March 2020 to 31st May 2021.
• Patient developed an hospital-acquired infection caused by P. aeruginosa during their ICU stay.

You may not qualify if:

• Patients \<18 years old.
• Patient without COVID-19 at the ICU admission.
• Patients with P. aeruginosa isolated \<48 hours following ICU admission.
• Patients who did not want to be included in the study.

Sponsors & Collaborators

• Central Hospital, Nancy, France: lead

MeSH Terms

Conditions

Pseudomonas Infections; COVID-19

Interventions

Observation

Condition Hierarchy (Ancestors)

Gram-Negative Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Infections; Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Methods; Investigative Techniques

Study Officials

• Arnaud Florentin, Dr

  a.florentin@chru-nancy.fr

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Doctor

Study Record Dates

• First Submitted: November 14, 2023
• First Posted: November 21, 2023
• Study Start: December 1, 2023
• Primary Completion: March 31, 2024
• Study Completion: April 20, 2024
• Last Updated: May 7, 2024

Record last verified: 2024-05